BioSpace News Archive

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

The global D-dimer testing market is set to witness a rapid rise in revenue from US$ 1,500.27 million in 2023 to US$ 2,269.31 million by 2032.

NuLiv Science, a leading plant-based nutraceutical ingredients company enabling people to lead healthier lives, announced the release of a study examining the efficacy and safety of Verbasnol™ (Rehmannia glutinosa Libosch leaf-based extract (RGLE)) for moderate to severe acne in females.

The Leukemia & Lymphoma Society’s Equity in Access Research Program announced the opening of its application process for the 2025 funding cycle.

GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that it will present at the Jefferies Global Healthcare Conference Private Biotech Day, taking place June 4th, 2024, in New York.

New funding enables healthŌme to enhance its genomics-based precision health offerings in the life and critical illness insurance sectors.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Medical Officer Dr. Raj Malik and Chief Commercial Officer Andrew Perry will participate in a fireside chat at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on Wednesday, May 29, at 8:30AM EDT.

Sinaptica Therapeutics, Inc. today announced that it has been selected to join StartUp Health’s Alzheimer’s Moonshot.

Enzolytics, Inc. announced today that it has entered into a Letter of Intent with Enogenesis (ENGN) for the specific use of the therapeutic application of ENGN’s patented Nitric Oxide Compound.

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that Health Canada has granted Cosentyx® (secukinumab) with a Notice of Compliance (NOC) for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic hidradenitis suppurativa therapy – representing a safe and efficacious new treatment option for Canadians living with the condition.